Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.

Literature DB >> 27151992

Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.

Jennifer R Brown¹, Wael A Harb², Brian T Hill³, Janice Gabrilove⁴, Jeff P Sharman⁵, Marshall T Schreeder⁶, Paul M Barr⁷, James M Foran⁸, Thomas P Miller⁹, Jan A Burger¹⁰, Kevin R Kelly¹¹, Daruka Mahadevan¹², Shuo Ma¹³, Yan Li¹⁴, Daniel W Pierce¹⁴, Evelyn Barnett¹⁵, Jeffrey Marine¹⁵, Monika Miranda¹⁵, Ada Azaryan¹⁶, Xujie Yu¹⁶, Pilar Nava-Parada¹⁵, Jay Mei¹⁵, Thomas J Kipps¹⁷.

Abstract

Entities: Disease

Keywords: BTK inhibitors; CC-292; chronic lymphocytic leukemia; refractory; relapsed; single-agent; small lymphocytic lymphoma

Mesh：

Substances：

Year: 2016 PMID： 27151992 PMCID： PMC5004476 DOI： 10.3324/haematol.2015.140806

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

13 in total

Review 1. B cell receptor signaling in chronic lymphocytic leukemia.

Authors: Jan A Burger; Nicholas Chiorazzi
Journal: Trends Immunol Date: 2013-08-05 Impact factor: 16.687

2. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

Authors: John C Byrd; Richard R Furman; Steven E Coutre; Jan A Burger; Kristie A Blum; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Yun Shaw; Elizabeth Bilotti; Cathy Zhou; Danelle F James; Susan O'Brien
Journal: Blood Date: 2015-02-19 Impact factor: 22.113

3. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.

Authors: Kami J Maddocks; Amy S Ruppert; Gerard Lozanski; Nyla A Heerema; Weiqiang Zhao; Lynne Abruzzo; Arletta Lozanski; Melanie Davis; Amber Gordon; Lisa L Smith; Rose Mantel; Jeffrey A Jones; Joseph M Flynn; Samantha M Jaglowski; Leslie A Andritsos; Farrukh Awan; Kristie A Blum; Michael R Grever; Amy J Johnson; John C Byrd; Jennifer A Woyach
Journal: JAMA Oncol Date: 2015-04 Impact factor: 31.777

4. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.

Authors: Wyndham H Wilson; Ryan M Young; Roland Schmitz; Yandan Yang; Stefania Pittaluga; George Wright; Chih-Jian Lih; P Mickey Williams; Arthur L Shaffer; John Gerecitano; Sven de Vos; Andre Goy; Vaishalee P Kenkre; Paul M Barr; Kristie A Blum; Andrei Shustov; Ranjana Advani; Nathan H Fowler; Julie M Vose; Rebecca L Elstrom; Thomas M Habermann; Jacqueline C Barrientos; Jesse McGreivy; Maria Fardis; Betty Y Chang; Fong Clow; Brian Munneke; Davina Moussa; Darrin M Beaupre; Louis M Staudt
Journal: Nat Med Date: 2015-07-20 Impact factor: 53.440

5. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans.

Authors: Erica K Evans; Richland Tester; Sharon Aslanian; Russell Karp; Michael Sheets; Matthew T Labenski; Steven R Witowski; Heather Lounsbury; Prasoon Chaturvedi; Hormoz Mazdiyasni; Zhendong Zhu; Mariana Nacht; Martin I Freed; Russell C Petter; Alex Dubrovskiy; Juswinder Singh; William F Westlin
Journal: J Pharmacol Exp Ther Date: 2013-05-24 Impact factor: 4.030

6. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors: Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal: Blood Date: 2008-01-23 Impact factor: 22.113

7. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

Authors: John C Byrd; Bonnie Harrington; Susan O'Brien; Jeffrey A Jones; Anna Schuh; Steve Devereux; Jorge Chaves; William G Wierda; Farrukh T Awan; Jennifer R Brown; Peter Hillmen; Deborah M Stephens; Paolo Ghia; Jacqueline C Barrientos; John M Pagel; Jennifer Woyach; Dave Johnson; Jane Huang; Xiaolin Wang; Allard Kaptein; Brian J Lannutti; Todd Covey; Maria Fardis; Jesse McGreivy; Ahmed Hamdy; Wayne Rothbaum; Raquel Izumi; Thomas G Diacovo; Amy J Johnson; Richard R Furman
Journal: N Engl J Med Date: 2015-12-07 Impact factor: 91.245

8. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Authors: John C Byrd; Jennifer R Brown; Susan O'Brien; Jacqueline C Barrientos; Neil E Kay; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Steve Devereux; Paul M Barr; Richard R Furman; Thomas J Kipps; Florence Cymbalista; Christopher Pocock; Patrick Thornton; Federico Caligaris-Cappio; Tadeusz Robak; Julio Delgado; Stephen J Schuster; Marco Montillo; Anna Schuh; Sven de Vos; Devinder Gill; Adrian Bloor; Claire Dearden; Carol Moreno; Jeffrey J Jones; Alvina D Chu; Maria Fardis; Jesse McGreivy; Fong Clow; Danelle F James; Peter Hillmen
Journal: N Engl J Med Date: 2014-05-31 Impact factor: 91.245

9. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors: Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal: N Engl J Med Date: 2013-06-19 Impact factor: 91.245

10. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors: John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal: N Engl J Med Date: 2013-06-19 Impact factor: 91.245

32 in total

Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.

Review 1. B cell receptor signaling in chronic lymphocytic leukemia.

2. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

3. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.

4. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.

5. Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans.

6. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

7. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

8. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

9. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

10. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Review 1. Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia.

Review 2. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.

Review 3. Targeted Therapy in Chronic Lymphocytic Leukemia (CLL).

Review 4. Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies.

Review 5. Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas.

Review 6. BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.

Review 7. PI3K signaling in cancer: beyond AKT.

Review 8. Targeting B Cell Signaling in Chronic Lymphocytic Leukemia.

Review 9. Targeting BTK in CLL: Beyond Ibrutinib.

Review 10. Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.